Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.65 |
| ▸ | BLM | P54132 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.65 |
| ▸ | GABRP | O00591 | 2/20 | 0.65 |
| ▸ | GABRD | O14764 | 2/20 | 0.65 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.65 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.65 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.65 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.65 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.65 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.65 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Alanine SCHEMBL18281085 | 1.00 | — | — | |
| Beta-Alanine SCHEMBL18281080 | 1.00 | — | — | |
| Beta-Alanine SCHEMBL21500 | 1.00 | — | — | |
| Beta-Alanine SCHEMBL20411566 | 1.00 | — | — | |
| Beta-Alanine SCHEMBL29449904 | 1.00 | — | — | |
| Beta-Alanine SCHEMBL11287803 | 0.96 | — | — | |
| Beta-Alanine SCHEMBL1762164 | 0.96 | — | — | |
| Beta-Alanine SCHEMBL9218103 | 0.96 | — | — | |
| Beta-Alanine SCHEMBL20516078 | 0.96 | — | — | |
| Beta-Alanine SCHEMBL65469 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342890-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2024-03-27 | — | — | EP | claimed |
| CN-102459325-A | Gastrostatin receptor activated glucagon compounds | UNIV INDIANA RES & TECH CORP | 2012-05-16 | — | — | CN | claimed |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2024-05-09 | — | — | US | disclosed |
| EP-3077008-B1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | HAN JIE (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | disclosed |
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. | 2021-12-28 | — | — | US | disclosed |
| WO-2021000067-A1 | CELL-BINDING MOLECULE-TUBULYSIN DERIVATIVE CONJUGATE AND PREPARATION METHOD THEREFOR | 杭州多禧生物科技有限公司 | 2021-01-07 | — | — | WO | disclosed |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | Han, Jie (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200268658-A1 | Degradable hydrogel under physiological conditions | HAN JIE (CN) | 2020-08-27 | — | — | US | disclosed |
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | Han, Jie (US) | 2020-04-21 | — | — | US | disclosed |
| US-10472404-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | ADDA BIOTECH INC. (CN) | 2019-11-12 | — | — | US | disclosed |
| US-20110028394-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | KAI PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2011003116-A2 | BETA-AMINO ACID COMPRISING ELECTROLYTE AND METHOD FOR THE DEPOSITION OF A METAL LAYER | ENTHONE INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| CN-101528658-A | Method for producing acrylic acid purified by crystallization from hydroxypropionic acid and apparatus therefor | STOCKHAUSEN CHEM FAB GMBH (DE) | 2009-09-09 | — | — | CN | disclosed |
| CN-101309688-A | Compositions and methods for sustained release of beta-alanine | NATURAL ALTERNATIVES INTERNAT (US) | 2008-11-19 | — | — | CN | disclosed |
| CN-101283095-A | Microbiological production of 3-hydroxypropionic acid | DEGUSSA (DE) | 2008-10-08 | — | — | CN | disclosed |
| CN-101068923-A | Improved alanine 2,3-aminomutases and related polynucleotides | CODEXIS INC (US) | 2007-11-07 | — | — | CN | disclosed |
| EP-0922031-A1 | A PROCESS FOR THE PREPARATION OF DIHYDROPYRIDINES | LUSOCHIMICA S.P.A. (IT) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998007698-A1 | A PROCESS FOR THE PREPARATION OF DIHYDROPYRIDINES | LUSOCHIMICA S.P.A. (IT) | 1998-02-26 | — | — | WO | disclosed |
| US-4383090-A | HIGH SPEED; COCURING AGENT OF POLYAMIDE-POLYLACTAM COPOLYMER; FILMS; CASTINGS; POTTING; ADHESIVES | DIAMOND SHAMROCK CORPORATION (US) | 1983-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208451-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | GLP1R, GIPR, IAPP | LMNA 4472/4885KMT2A 3645/4885TSHR 213/4885 |
| US-20200268658-A1 | Degradable hydrogel under physiological conditions | PTMS, TRHDE, PHYKPL | LMNA 1938/4885KMT2A 4303/4885TSHR 1255/4885 |
| US-10626156-B2 | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs | NOS2, EGLN2, HPGD | LMNA 1576/4885KMT2A 3057/4885TSHR 3922/4885 |
| US-20240150426-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | LMNA 1576/4885KMT2A 3057/4885TSHR 3922/4885 |
| US-10472404-B2 | Protein and protein conjugate for diabetes treatment, and applications thereof | GLP1R, GIPR, IAPP | LMNA 4472/4885KMT2A 3645/4885TSHR 213/4885 |
| US-20110028394-A1 | THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS | PTH1R, PTMS, TPX2 | LMNA 1737/4885KMT2A 3760/4885TSHR 112/4885 |
| US-20200291086-A1 | BIOREVERSABLE PROMOIETIES FOR NITROGEN-CONTAINING AND HYDROXYL-CONTAINING DRUGS | NOS2, EGLN2, HPGD | LMNA 1576/4885KMT2A 3057/4885TSHR 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.